Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Adaptive Pathways: Possible Next Steps for Payers in Preparation for Their Potential Implementation.

Autor: Vella Bonanno P; Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of StrathclydeGlasgow, United Kingdom., Ermisch M; Pharmaceutical Department, National Association of Statutory Health Insurance FundsBerlin, Germany., Godman B; Department of Pharmacoepidemiology, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of StrathclydeGlasgow, United Kingdom.; Health Economics Centre, University of Liverpool Management SchoolLiverpool, United Kingdom.; Division of Clinical Pharmacology, Karolinska InstitutetStockholm, Sweden., Martin AP; Health Economics Centre, University of Liverpool Management SchoolLiverpool, United Kingdom., Van Den Bergh J; Department of HealthEcorys, Rotterdam, Netherlands., Bezmelnitsyna L; National Research Institution for Public HealthMoscow, Russia., Bucsics A; Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA)Brussels, Belgium., Arickx F; Department of Pharmaceutical Policy, National Institute for Health and Disability InsuranceBruxelles, Belgium., Bybau A; Zilveren Kruis AchmeaLeiden, Netherlands., Bochenek T; Department of Drug Management, Faculty of Health Sciences, Jagiellonian University Medical CollegeKraków, Poland., van de Casteele M; Department of Pharmaceutical Policy, National Institute for Health and Disability InsuranceBruxelles, Belgium., Diogene E; Clinical Pharmacology Service, University Hospital Vall d'Hebron, Universitat Autonoma de BarcelonaBarcelona, Spain., Eriksson I; Department of Healthcare Development, Stockholm County CouncilStockholm, Sweden.; Department of Medicine Solna, Karolinska InstitutetStockholm, Sweden., Fürst J; Medicinal Products Department, Health Insurance Institute of SloveniaLjubljana, Slovenia., Gad M; Global Health and Development Group, Imperial CollegeLondon, United Kingdom., Greičiūtė-Kuprijanov I; Department of Pharmacy, Ministry of Health of the Republic of LithuaniaVilnius, Lithuania., van der Graaff M; National Health Care Institute (ZIN)Diemen, Netherlands., Gulbinovic J; Department of Pathology, Forensic Medicine and Pharmacology, Faculty of Medicine, Vilnius UniversityVilnius, Lithuania.; State Medicines Control AgencyVilnius, Lithuania., Jones J; Scottish Medicines ConsortiumGlasgow, United Kingdom., Joppi R; Clinical Research and Drug Assessment UnitVerona, Italy., Kalaba M; Pediatric Cardiology, Primary Healthcare Centre 'Zemun'Belgrade, Serbia., Laius O; Department of Post-authorisation Safety, State Agency of MedicinesTartu, Estonia., Langner I; Wissenschaftliches Institut der AOKBerlin, Germany., Mardare I; Faculty of Medicine, Public Health and Management Department, 'Carol Davila' University of Medicine and Pharmacy BucharestBucharest, Romania., Markovic-Pekovic V; Ministry of Health and Social WelfareBanja Luka, Bosnia and Herzegovina.; Department of Social Pharmacy, Medical Faculty, University of Banja LukaBanja Luka, Bosnia and Herzegovina., Magnusson E; Department of Health Services, Ministry of HealthReykjavík, Iceland., Melien O; Norwegian Directorate for HealthOslo, Norway., Meshkov DO; Department of HealthEcorys, Rotterdam, Netherlands., Petrova GI; Department of Social Pharmacy and Pharmacoeconomics, Faculty of Pharmacy, Medical University of SofiaSofia, Bulgaria., Selke G; Wissenschaftliches Institut der AOKBerlin, Germany., Sermet C; Institut de Recherche et Documentation en Economie de la Santé (IRDES)Paris, France., Simoens S; KU Leuven Department of Pharmaceutical and Pharmacological SciencesLeuven, Belgium., Schuurman A; National Health Care Institute (ZIN)Diemen, Netherlands., Ramos R; Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)Lisboa, Portugal., Rodrigues J; Health Technology Assessment, Pricing and Reimbursement Department, Central Administration of the Health System, National Authority of Medicines and Health Products (I.P., INFARMED)Lisboa, Portugal., Zara C; Barcelona Health Region, Catalan Health ServiceBarcelona, Spain., Zebedin-Brandl E; Department of Pharmaceutical Affairs, Main Association of Austrian Social Insurance InstitutionsVienna, Austria., Haycox A; Health Economics Centre, University of Liverpool Management SchoolLiverpool, United Kingdom.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2017 Aug 23; Vol. 8, pp. 497. Date of Electronic Publication: 2017 Aug 23 (Print Publication: 2017).